These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18697257)

  • 21. Potentiation of botulinum toxin type A with oral anti-spasticity medications in the management of focal spasticity.
    Dai A
    J Rehabil Med; 2007 Mar; 39(2):189; author reply 189. PubMed ID: 17351705
    [No Abstract]   [Full Text] [Related]  

  • 22. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of dantrolene sodium and diazepam in the treatment of spasticity.
    Glass A; Hannah A
    Paraplegia; 1974 Nov; 12(3):170-4. PubMed ID: 4616209
    [No Abstract]   [Full Text] [Related]  

  • 24. [Spasticity: therapy of increased reflexes or movement disorder?].
    Dietz V
    Nervenarzt; 1990 Oct; 61(10):581-6. PubMed ID: 2274090
    [No Abstract]   [Full Text] [Related]  

  • 25. [Management of spasticity in children with cerebral palsy].
    Matthews DJ; Balaban B
    Acta Orthop Traumatol Turc; 2009; 43(2):81-6. PubMed ID: 19448346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dantrolene sodium for treatment of spasticity.
    Med Lett Drugs Ther; 1974 Jul; 16(15):61-2. PubMed ID: 4843632
    [No Abstract]   [Full Text] [Related]  

  • 27. Dantrolene sodium in athetoid cerebral palsy.
    Chyatte SB; Birdsong JH; Roberson DL
    Arch Phys Med Rehabil; 1973 Aug; 54(8):365-8. PubMed ID: 4578848
    [No Abstract]   [Full Text] [Related]  

  • 28. [Medical treatment of spasticity].
    Rode G; Maupas E; Luaute J; Courtois-Jacquin S; Boisson D
    Neurochirurgie; 2003 May; 49(2-3 Pt 2):247-55. PubMed ID: 12746699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intrathecal baclofen for muscle spasticity and pain--two case reports.
    Al Khudhairi D; Rababa A; Saddiqui MN
    Middle East J Anaesthesiol; 2006 Jun; 18(5):971-6. PubMed ID: 17094537
    [No Abstract]   [Full Text] [Related]  

  • 30. Spasticity treatment facilitates direct care delivery for adults with profound intellectual disability.
    Charles PD; Gill CE; Taylor HM; Putman MS; Blair CR; Roberts AG; Ayers GD; Konrad PE
    Mov Disord; 2010 Mar; 25(4):466-73. PubMed ID: 20131401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Botulinum toxin type A in the treatment plan for cerebral palsy].
    Strobl W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():30-5. PubMed ID: 15506050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of Dantrium on spasticity in paraplegic and tetraplegic patients (author's transl)].
    van Laere M; Leus P; Mastelinck C
    J Belge Med Phys Rehabil; 1978; 1(2):189-99. PubMed ID: 757420
    [No Abstract]   [Full Text] [Related]  

  • 33. Cerebral palsy: the whys and hows.
    Fairhurst C
    Arch Dis Child Educ Pract Ed; 2012 Aug; 97(4):122-31. PubMed ID: 22868578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Intrathecal baclofen for treatment of spasticity in patient with cerebral palsy--a preliminary report].
    Jóźwiak M; Idzior M; Huber J; Szulc A; Grottel K
    Chir Narzadow Ruchu Ortop Pol; 2003; 68(4):253-9. PubMed ID: 14702678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The use of botulotoxin type A(dysport)in the complex therapy of patients with post-stroke spasticity].
    Khat'kova SE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(12):57-9. PubMed ID: 19255982
    [No Abstract]   [Full Text] [Related]  

  • 36. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
    Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration.
    Meyler WJ; Bakker H; Kok JJ; Agoston S; Wesseling H
    J Neurol Neurosurg Psychiatry; 1981 Apr; 44(4):334-9. PubMed ID: 7241161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic management of spasticity following stroke.
    Gallichio JE
    Phys Ther; 2004 Oct; 84(10):973-81. PubMed ID: 15449979
    [No Abstract]   [Full Text] [Related]  

  • 39. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
    Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD
    Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of dantrolene sodium and diazepam in the treatment of spasticity.
    Schmidt RT; Lee RH; Spehlmann R
    J Neurol Neurosurg Psychiatry; 1976 Apr; 39(4):350-6. PubMed ID: 778344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.